| Nov 13 |
UroGen Pharma: Choice Based On Near-Term High-Value PDUFA
|
| Nov 9 |
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target
|
| Nov 7 |
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
|
| Nov 6 |
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 6 |
UroGen Pharma GAAP EPS of -$0.55 beats by $0.26, revenue of $25.2M beats by $1M
|
| Nov 6 |
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
|
| Nov 5 |
UroGen Pharma Q3 2024 Earnings Preview
|
| Nov 5 |
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
|
| Oct 30 |
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
|
